Brief: Cantargia Presents Preclinical Data Demonstrating Unique Treatment Effects Of Nadunolimab On Pancreatic Cancer Stromal Cells
14/09/2022 04:30
Sept 13 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA PRESENTS PRECLINICAL DATA DEMONSTRATING UNIQUE
TREATMENT EFFECTS OF NADUNOLIMAB ON PANCREATIC CANCER STROMAL
CELLS
Source text for Eikon: ID:nPreV3mkMa
Further company coverage: CANTA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML